

**Remarks**

Claims 2-4, 6-30, and 32-44 have been cancelled. Claim 5 has been amended to depend from Claim 1 and to address a typographical error. Claim 1 has been amended in an attempt to comply with the requirement for restriction. Applicants assert that Claim 1 presents no issue of new matter. Basis for the amendments to Claim 1 may be found at least at page 4, lines 16 and 22-23; page 7, lines 3, 5, and 13-14; and page 8, lines 11-12. Entry of the amendments and allowance of the claims are respectfully requested.

The scope of claim 1, as amended, most closely aligns with the invention of Group III in the restriction requirement. Applicants have expanded the definition of variable X to include both phenyl and phenyl substituted with fluorine and the definition of group Y to include both benzothienyl and benzothienyl substituted with phenyl. Applicants assert that the subject matter as currently claimed fully meets the requirements of unity of invention. Should the examiner disagree and find that the invention as now claimed lacks unity of invention, Applicants elect the species of Example 70, with traverse.

Respectfully submitted,

/Robert D. Titus/

Robert D. Titus  
Attorney for Applicants  
Registration No. 40,206  
Phone: 317-277-3729

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

October 25, 2007